rupiya.io
⠋Loading...
0%
❯ Parsing revenue segments...
Apollo Hospitals is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Apollo Hospitals Enterprise Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Metric | 1 Year | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|
| Sales | — | — | — | — |
| Profit | — | — | — | — |
| Stock Price | — | — | — | — |
| ROE | — | — | — | — |
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,357 Cr | ₹5,129 Cr | ₹6,150 Cr |
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,264 Cr | ₹4,302 Cr | ₹4,418 Cr | ₹4,847 Cr | ||||||||
| Expenses | ₹3,780 Cr | ₹3,814 Cr | ₹3,909 Cr | ₹4,219 Cr | ||||||||
| Operating Profit | ₹484 Cr | ₹488 Cr | ₹509 Cr | ₹628 Cr |
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹70 Cr | ₹70 Cr | ₹70 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹2,907 Cr | ₹3,102 Cr | ₹3,262 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹373 Cr | ₹-356 Cr | ₹-63 Cr | — |
| Mar 2016 | ₹470 Cr | ₹-759 Cr | ₹392 Cr | — |
| Mar 2017 | ₹597 Cr | ₹-888 Cr | ₹330 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 |
| Ratio | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 14.7% | 14.9% | 13.5% | — | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | 16.2% | 16.4% | 15.1% | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt/Equity | 0.4 | 0.5 | 0.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 8.2 | 14.7 | 13.8 | — | — | — | — | — | — | — | — | — | — |
| Year | Type | Amount (₹) |
|---|---|---|
| FY24 | Interim | ₹19.97 |
| FY23 | Final | ₹8.56 |
| FY22 | Final | ₹10.24 |
| FY21 | Interim | |
| FY20 | Interim | |
| FY19 | Final |
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
| Torrent Pharmaceuticals Ltd | ₹1,49,446 Cr | 69.7 | 0.00% | +15.25% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.
Deep-dive analysis of Apollo Hospitals's competitive moat, management quality, and growth runway available with Premium.
Premium| Expenses | ₹3,681 Cr | ₹4,392 Cr | ₹5,465 Cr |
| Operating Profit | ₹676 Cr | ₹737 Cr | ₹684 Cr |
| OPM % | 16.0% | 14.0% | 11.0% |
| Other Income | ₹18 Cr | ₹47 Cr | ₹92 Cr |
| Depreciation | ₹168 Cr | ₹212 Cr | ₹264 Cr |
| Interest | ₹119 Cr | ₹118 Cr | ₹180 Cr |
| Profit Before Tax | ₹407 Cr | ₹455 Cr | ₹332 Cr |
| Tax | ₹407 Cr | ₹455 Cr | ₹332 Cr |
| Net Profit | ₹315 Cr | ₹335 Cr | ₹235 Cr |
| EPS (₹) | 22.8 | 24.4 | 17.0 |
| Dividend Payout % | 25% | 24% | 35% |
Register free to see 9 more years.
| OPM % | 11.0% | 11.0% | 12.0% | 13.0% |
| Depreciation | ₹153 Cr | ₹159 Cr | ₹167 Cr | ₹163 Cr |
| Interest | ₹100 Cr | ₹95 Cr | ₹106 Cr | ₹111 Cr |
| Net Profit | ₹162 Cr | ₹146 Cr | ₹173 Cr | ₹249 Cr |
| EPS (₹) | 10.7 | 10.1 | 11.6 | 16.2 |
Register free to see 8 more quarters.
| Borrowings | ₹1,344 Cr | ₹1,992 Cr | ₹2,834 Cr |
| Other Liabilities | ₹1,029 Cr | ₹1,296 Cr | ₹1,195 Cr |
| Total Liabilities | ₹5,350 Cr | ₹6,459 Cr | ₹7,360 Cr |
| Assets |
| Fixed Assets | ₹2,681 Cr | ₹3,244 Cr | ₹3,997 Cr |
| Investments | ₹322 Cr | ₹311 Cr | ₹352 Cr |
| Receivables | — | — | — |
| Inventory | — | — | — |
| Cash & Equivalents | — | — | — |
| Other Assets | ₹1,855 Cr | ₹2,372 Cr | ₹2,448 Cr |
| Total Assets | ₹5,350 Cr | ₹6,459 Cr | ₹7,360 Cr |
Register free to see 9 more years.
| Mar 2022 |
| Mar 2023 |
| Mar 2024 |
| Mar 2025 |
Register free to see 9 more years.
| — |
| — |
| Current Ratio | 1.4 | 1.7 | 1.7 | — | — | — | — | — | — | — | — | — | — | — | — |
| Quick Ratio | 1.0 | 1.2 | 1.2 | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | 14.3% | 15.2% | 13.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| NPM % | 8.6% | 9.1% | 7.8% | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 16.7 | 16.5 | 14.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| PEG Ratio | 2.0 | 1.9 | 1.2 | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Turnover | 1.3 | 1.5 | 1.0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 6.3 | 5.1 | 5.9 | — | — | — | — | — | — | — | — | — | — | — | — |
Register free to see 12 more years of ratio trends.